| Chapter title |
Alectinib
|
|---|---|
| Chapter number | 17 |
| Book title |
Small Molecules in Oncology
|
| Published in |
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2018
|
| DOI | 10.1007/978-3-319-91442-8_17 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-991441-1, 978-3-31-991442-8
|
| Authors |
M. Herden, Cornelius F. Waller, Herden, M., Waller, Cornelius F. |
| Abstract |
Alectinib is an ATP-competitive small molecule and a second-generation inhibitor of ALK. EML4-ALK rearrangement is found in 3-5% of patients with NSCLC. The first-generation inhibitor crizotinib has changed the treatment dramatically, though most of the patients show disease progression within one year. Extra-thoracic progress, i.e., CNS metastases is common. The second-generation inhibitor alectinib has shown significant improvement in PFS and a remarkable prolongation of time to CNS progression. Alectinib has received approval as first-line therapy as well as second-line therapy after crizotinib failure. The toxicity profile is favorable compared to crizotinib and chemotherapy. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 42 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 14% |
| Student > Ph. D. Student | 4 | 10% |
| Student > Master | 4 | 10% |
| Student > Bachelor | 3 | 7% |
| Professor | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 21 | 50% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 19% |
| Biochemistry, Genetics and Molecular Biology | 5 | 12% |
| Chemistry | 3 | 7% |
| Agricultural and Biological Sciences | 1 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Other | 2 | 5% |
| Unknown | 22 | 52% |